Status:
COMPLETED
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Lead Sponsor:
Nektar Therapeutics
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of ...
Detailed Description
NKTR-102 (Topoisomerase I Inhibitor Polymer Conjugate) is a polyethylene glycol (PEG) conjugate of irinotecan. Irinotecan is a topoisomerase I inhibitor approved worldwide. In the US, irinotecan is in...
Eligibility Criteria
Inclusion
- metastatic colorectal cancer
- tumor with k-ras mutation
Exclusion
- More than 1 prior regimen for treatment of metastatic disease
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00856375
Start Date
December 1 2008
End Date
December 1 2014
Last Update
July 12 2021
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigator Site - Peoria
Peoria, Arizona, United States, 85381
2
Investigator Site - Burbank
Burbank, California, United States, 91505
3
Investigator Site - Los Angeles
Los Angeles, California, United States, 90033
4
Investigator Site - Vallejo
Vallejo, California, United States, 94589